Catherine Thompson - Concepedia

Concepedia

Author

Catherine Thompson

Allergan (United States)

Also Known As

C Thompson, C. THOMPSON, C. Thompson, C.J. Thompson, CATHERINE THOMPSON, Catherine J. Thompson, Catherine Thompson, Clare Buckley

61

Publications

3.8K

Citations

21

H-Index

54

Concepts

All Affiliations

Allergan (United States)Allergan (United Kingdom)University of Toronto Vanderbilt University Royal Hallamshire Hospital

CT

About

Catherine Thompson is an author at Allergan (United States) specializing in medicine, urology, and urogynecology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	2K
2	Health Sciences	2	2	81
3	Public Health	1	1	14
4	Biomedical Engineering	1	1	62
5	Diagnostic Sciences	1	1	19

Catherine Thompson

×

26

Publications

3.8K

Citations

20

H-Index

	Year	Citations
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Eugenia Abaleke, Mustafa Abbas, Sadia Abbasi, The Lancet Long CovidAntimicrobial StewardshipAntibioticsClinical InfectionPlatform Trial	2021	555
Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double-Blind, Placebo-Controlled Trial Francisco Cruz, Sender Herschorn, Philip J. Aliotta, European Urology UrologyVoiding DysfunctionFemale UrologyNeurogenic Detrusor OveractivityPlacebo-controlled Trial	2011	467
OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial Christopher R. Chapple, Karl‐Dietrich Sievert, Scott MacDiarmid, European Urology Urological ResearchUrologyVoiding DysfunctionUrinary IncontinencePlacebo-controlled Trial	2013	401
OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial Victor W. Νitti, Roger R. Dmochowski, Sender Herschorn, The Journal of Urology	2012	399
Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial Roger R. Dmochowski, Christopher R. Chapple, Victor W. Νitti, The Journal of Urology	2010	397
Phase 3 Efficacy and Tolerability Study of OnabotulinumtoxinA for Urinary Incontinence From Neurogenic Detrusor Overactivity David Ginsberg, Angelo E. Gousse, V. Keppenne, The Journal of Urology	2012	345
OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial Victor W. Νitti, Roger R. Dmochowski, Sender Herschorn, The Journal of Urology	2016	328
A Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Multiple Treatments of Botulinum Toxin Type A (BoNTA) for the Prophylaxis of Episodic Migraine Headaches Maja Relja, AC Poole, J Schoenen, Cephalalgia Cluster HeadacheTranslational MedicineMultiple TreatmentsStrokePharmacotherapy	2007	125
OnabotulinumtoxinA Improves Health-Related Quality of Life in Patients With Urinary Incontinence Due to Idiopathic Overactive Bladder: A 36-Week, Double-Blind, Placebo-Controlled, Randomized, Dose-Ranging Trial Clare J. Fowler, Stephen M. Auerbach, David A. Ginsberg, European Urology UrologyVoiding DysfunctionHealth-related QualityFemale UrologyDose-ranging Trial	2012	89
OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Activity Regardless of Concomitant Anticholinergic Use or Neurologic Etiology David A. Ginsberg, Francisco Cruz, Sender Herschorn, Advances in Therapy	2013	81

Page 1